Stay updated with breaking news from Mg Adl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.
Two doses of batoclimab were evaluated for their effectiveness in patients with generalized myasthenia gravis (MG) who were seropositive.
The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.
The investigation evaluated if symptom signatures of myasthenia gravis exacerbations could be evaluated using real-world data gathered via a smartphone-based research platform.
Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.